Abstract
Anti-heat shock cognate protein 71 antibody (HSC71 Ab) formation in the sera of myasthenia gravis (MG) patients was measured, and the correlation between HSC71 Ab titers, clinical features and therapy efficacies for MG patients were examined. Clinical evaluations were performed according to the MG Foundation of America (MGFA) clinical classification. Therapy efficacies were measured using the MG activities of daily living (MG-ADL) score. Before treatment, 38 out of 48 serum samples (79%) from MG patients showed positive HSC71 Ab titers. In the “therapy-responsive group”, HSC71 Ab titers significantly reduced, along with patient clinical improvements. Conversely, in the “therapy-resistant group”, HSC71 Ab titers did not decline. The use of tacrolimus resulted in improvement in clinical manifestations together with a reduction in HSC71 Ab titers in the “therapy-resistant group”. Thus, measurement of HSC71 Ab in the sera of MG patients seemed useful, as it appeared to reflect the effectiveness of treatment and allowed prediction of prognosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
